An Intrinsic Calculation For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Suggests It's 32% Undervalued
来源：雅虎金融 2019-04-20 02:00How far off is Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expect
来源：Zacks 2019-04-17 21:30It has been about a month since the last earnings report for Catalyst Pharmaceutical (CPRX). Shares have added about 58.1% in that time frame, outperforming the S&P 500.Will the recent positive trend
来源：Motley Fool 2019-04-04 22:24What happenedCatalyst Pharmaceuticals (NASDAQ: CPRX), an orphan drugmaker, gained a whopping 77% last month, according to data from S&P Global Market Intelligence. What sparked this breakout?Catalyst'
来源：Motley Fool 2019-03-31 21:00If you're thinking about investing in biotech stocks, there's no time like the present. Many biotechs have plenty of catalysts in the near future that could light a fire beneath their share prices. Bu
来源：Zacks 2019-03-30 01:30Friday, March 29, 2019The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Phillip Morris
The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO
来源：Shanthi Rexaline 2019-03-28 19:54Here'saroundupoftopdevelopmentsinthebiotechspaceoverthelast24hours.ScalingThePeaks(Biotechstockshitting52-weekhighsonMarch27)BaxterInternationalInc(NYSE:BAX)CatalystPharmaceuticalsInc(NASDAQ:CPRX)Cons
来源：Benzinga 2019-03-26 19:36Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks(Biotech stocks hitting 52-week highs on March 25)Axsome Therapeutics Inc (NASDAQ: AXSM)Catalyst Pharm
来源：Motley Fool 2019-03-25 20:09With the economy showing signs of cooling off, investors will have to tread carefully when it comes to buying growth stocks. That said, there are still a handful of names worth buying, even in this un
The Daily Biotech Pulse: Immutep Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback
来源：Shanthi Rexaline 2019-03-22 20:16Here'saroundupoftopdevelopmentsinthebiotechspaceoverthelast24hours.ScalingThePeaks(Biotechstockshitting52-weekhighsonMarch21)AbbottLaboratories(NYSE:ABT)BaxterInternationalInc(NYSE:BAX)BiohavenPharmac
来源：DowjonesNews 2019-03-20 19:59MWCatalystPharmaceuticalsstockpricetargetraisedto$10from$9atOppenheimer(END)DowJonesNewswiresMarch20,201907:59ET(11:59GMT)Copyright(c)2019DowJones&Company,Inc.
来源：Thomson Reuters StreetEvents 2019-03-20 06:16Q4 2018 Catalyst Pharmaceuticals Inc Earnings CallCoral Gables Mar 19, 2019 (Thomson StreetEvents) -- Edited Transcript of Catalyst Pharmaceuticals Inc earnings conference call or presentation Tuesday
来源：Motley Fool 2019-03-20 05:23What happenedShares of Catalyst Pharmaceuticals (NASDAQ: CPRX), a maker of drugs for rare diseases, rose by as much as 19.1% on more than three times the average daily volume today. What sparked this
来源：Zacks 2019-03-20 02:26Catalyst Pharmaceuticals, Inc. CPRX reported a loss of 14 cents per share in the fourth quarter of 2018, wider than the Zacks Consensus Estimate of a loss of 12 cents and the year-ago loss of 6 cents.
来源：Shanthi Rexaline 2019-03-19 19:40Here'saroundupoftopdevelopmentsinthebiotechspaceoverthelast24hours.ScalingThePeaks(Biotechstockshitting52-weekhighsonMarch18)AstraZenecaplc(NYSE:AZN)(receivedorphandrugstatusforsaracatinib,itsinvestig
来源：Associated Press 2019-03-19 04:52CORAL GABLES, Fla. (AP) _ Catalyst Pharmaceutical Partners Inc. (CPRX) on Monday reported a loss of $14.5 million in its fourth quarter.On a per-share basis, the Coral Gables, Florida-based company sa